GlassScriptPhysician profile
David A Racher
NPI 1245293042
$12,512.83
in general payments reported to CMS, 2019-2025
62 companies · $30.92 in 2025
The $30.92 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,486 · 2020: $2,180 · 2021: $2,254 · 2022: $1,867 · 2023: $2,524 · 2024: $172 · 2025: $30.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,757.36 | 2021-2024 | |
| Amgen INC. | $1,008.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $780.68 | 2019-2023 | |
| Biogen, INC. | $718.47 | 2019-2023 | Vumerity |
| Teva Pharmaceuticals USA, INC. | $579.63 | 2019-2023 | Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $550.79 | 2019-2023 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $541.00 | 2019-2023 | Ultomiris |
| Ucb, INC. | $450.07 | 2019-2023 | Briviact |
| Allergan, INC. | $437.82 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $436.11 | 2019-2025 | Ongentys, Ingrezza |
| Genzyme Corporation | $393.47 | 2019-2022 | |
| Lilly USA, LLC | $312.62 | 2019-2023 | Emgality, Amyvid |
| Adamas Pharmaceuticals, INC. | $302.69 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $273.44 | 2019-2022 | |
| Pfizer INC. | $253.26 | 2019-2023 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Racher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.